top of page


Coronavirus Disease 2019 (COVID-19) is the greatest public health challenge in over a century. Basic questions about its prevention, diagnosis, treatment and prognosis remain unanswered, hindering evidence-based clinical decision-making.

We have an established governance structure, signed Membership & Data Sharing Agreements with 51 hospitals across eight provinces, with the capability to collect and analyze valuable data on patient demographics, medical management, and social determinants of health.

CCEDRRN has completed studies on registry methods, COVID-19 treatments and prognosis, diagnostic testing, patient-reported outcomes, and developed 3 clinical decision rules to guide COVID-19 management has become the third largest COVID-19 registry listed with the World Health Organization. 

From this network, 19 peer-reviewed journal articles have been published, 5 manuscripts are undergoing peer review and 4 further studies are in the analysis phase.

Primary Investigators

Dr. Corinne Hohl

Principal Investigator

(Associate Professor, University of British Columbia; BC) is an emergency physician and health services researcher with expertise in multi-centre observational cohort studies and quasi-experimental designs. She holds over $13M in research funding as nominated Principal Applicant, with over 70 peer-reviewed publications.

Dr. Laurie Morrison

Co-Principal Investigator

(Professor, University of Toronto) is a senior resuscitation scientist with experience in international networks, registries, randomized trials and clinical decision rules. She is Director of the Collaborative Specialization Resuscitation Sciences graduate training and mentorship, and will coordinate our graduate students and mentoring of Early Career Researchers.

Dr. Jeffrey Perry

Co-Principal Investigator

(Professor, University of Ottawa) is a world-leading expert in clinical decision rules, and has derived, validated and implemented multiple influential emergency clinical decision rules.

Pipetting Samples


In Year 2 (June 1 2021-March 31 2022), we aim to leverage our established infrastructure to create a national vaccine evaluation platform in partnership with provincial Public Health partners.

We will evaluate vaccine effectiveness (VE) and the duration of protection in priority populations who commonly receive care in Emergency Departments for symptomatic and severe COVID-19, and were inadequately evaluated in or excluded from phase 3 vaccine effectiveness trials.

Our specific objectives are to evaluate:

  • The effectiveness of COVID-19 vaccines for preventing severe COVID-19 in priority groups, including in racialized and Indigenous communities, individuals of lower socioeconomic status, those with active comorbidity (e.g., active cancer), at the extremes of ages, in pregnant and breastfeeding women, and in otherwise marginalized groups;


  • The effectiveness of COVID-19 vaccines in preventing severe disease, hospitalization and mortality, as delivered in the real-world, including single doses of vaccines authorized as two-dose series, delayed boosters, and receipt of vaccines from different manufacturers; and


  • The duration of vaccine protection from symptomatic COVID-19 in the general population and in specific groups (e.g., elderly with immune senescence), by vaccine type, for single doses of vaccines authorized as two-dose series, and in individuals receiving a delayed booster.

Pipetting Samples


CCEDRRN is governed primarily by the Executive Committee which oversees the day-to-day operations of the network, and the Steering Committee which provides oversight and direction to the network. 

CCEDRRN's governance structure provides for a robust, scientific peer-review process ensuring data integrity to allow for world-class, high-quality research published by the network.


The network is generously funded by:

CHU de Quebec.png
SHRF logo NEW.png
Client 6
bottom of page